Demand is real; footing is the question
The demand is genuine — strong buzz, patient requests, overseas popularity. But demand and popularity don't establish regulatory footing. The regulatory status and availability of these specific products in the US is a significant, evolving question, and the fact that patients want it (and competitors may advertise it) doesn't make a given product legitimately available to you to offer as marketed. This is the classic regenerative-category trap, sharpened: high demand, unclear footing.
The diligence requirement
Because demand outruns clarity, this is a category requiring careful regulatory and sourcing diligence with counsel before you build anything around it — not an assumption that availability equals legality. Some of what's trendy may not survive that diligence in a form you'd want to offer; some may. The discipline is doing the owner-level regulatory work before the clinical adoption, exactly as with the broader regenerative wave.
Lead or decline cleanly
Watch the category as a demand signal, do the diligence, and then either offer what's genuinely defensible on solid footing or decline cleanly — "we don't offer products outside proper channels, here's what we'd recommend instead" — which is a position of strength. What you must not do is chase the viral demand by sourcing or offering something whose US footing you haven't confirmed.
What to do
- Treat polynucleotide boosters as high-demand, unclear-footing — a category requiring diligence, not an assumption of availability.
- Do regulatory and sourcing diligence with counsel before building any offering.
- Don't let patient demand or competitor activity substitute for footing.
- Lead on what's defensible, decline cleanly on what's not.
